Basilea Pharmaceutica International Ltd, Allschwil
Basilea is committed to discovering, developing and commercializing innovative drugs to meet the needs of patients with severe bacterial and fungal infections. We have successfully launched two hospital brands, Cresemba® for the treatment of invasive fungal infections and Zevtera® for the treatment of bacterial infections. We have preclinical and clinical anti-infective assets in our portfolio. We are located in the Basel area and listed on the SIX Swiss Exchange (SIX: BSLN).
Date, time and room information
May 5, 16:00 - 16:15, room Osaka/Samarkand
Category
Commercial stage company
Title of the presentation
Basilea – a world-leading antibacterial/antifungal business
Speaker information
| Name | Position | Institution |
|---|---|---|
| Mark Jones | Head of Global Affairs | Basilea Pharmaceutica |
